New Study Affirms Financial and Public Health Advantages of Treating Drug-Resistant TB with BPaL-Based Regimens in India
A new economic evaluation has added powerful evidence to the already strong case for wide, global adoption of BPaL and
A new economic evaluation has added powerful evidence to the already strong case for wide, global adoption of BPaL and
The World Health Organization’s (WHO) new guidance on Country Preparedness for the Introduction and Appropriate Use of Antibiotics highlighted TB
Regional meeting in Peru convened by PeerLINC, a global peer-to-peer initiative, brings together 20 countries to accelerate collaboration and scale-up
TB Alliance’s third licensed manufacturer makes pretomanid available through the Global Drug Facility, further improving affordability and access TB Alliance
The PeerLINC Knowledge Hub, an innovative peer-to-peer initiative that connects experts from countries that rapidly adopted new six-month all-oral drug-resistant
Stop TB Canada has announced a streamlined process to speed up the availability of pretomanid, a key drug in the
Throughout 2024, one of TB Alliance’s foremost priorities has been ensuring that pretomanid and BPaL-based regimens reach all people with
MANILA (September 3, 2024) – A delegation of experts from Brazil’s National TB Program visited Manila recently to collaborate with
MANILA (25 March 2024)—TB Alliance’s new Peer-to-Peer Learning for Innovative Cures (PeerLINC) Knowledge Hub launched today in Manila, with funding
Indonesia, Kyrgyzstan, Philippines, Ukraine, Uzbekistan, and Viet Nam presented results of LIFT-TB operational research program at the Union Conference on